Arcellx

Edit info

Founded: 2015

Location: Gaithersburg, MD

Employee range: 50 - 200

Clinical stage: Clin2

Therapy area: Multiple myeloma (ODD)

Drug types: ONC

Lead product: iMMagine-1

Funding: $128.8M stock Jun 2022; $142M IPO Feb 2022; $115M C Apr 2021; $85M B Oct 2019

arcellx.com

linkedin.com

job board

Drug notes:

iMMagine-2 Clin2 multiple myeloma; ACLX-001 Clin1 multiple myeloma; ACLX-002 Clin0 AML/MDS; ACLX-003 Clin0 AML/MDS; 4 undisclosed programs RD multiple myeloma, AML, SCLC, hepatocellular carcinoma

About:

Arcellx is developing immunotherapies to treat cancer. Chimeric antigen receptor (CAR) T-cells are the latest innovation to identify and eliminate cancer cells, yet there is still more room for improvement. Arcellx’s unique approach involves their novel D-Domain technology, a small, stable, fully synthetic binding agent that can be combined with CARs to improve target specificity and enhance binding affinity. From the D-Domain, Arcellx can generate diverse libraries of proprietary target-binding domains which serve as the foundation of their proprietary ddCAR and ARC-SparX platforms. Arcellx is currently developing cell therapies treatments for multiple myeloma, acute myeloid leukemia and solid tumors, the first of which is now in Phase 2 clinical trials.